| Autor: |
Ridley, Anne, Frampton, Jon, Dijke, Peter ten, Heldin, Carl-Henrik, Lahn, Michael, Berry, Brandi, Kloeker, Susanne, Yingling, Jonathan M. |
| Zdroj: |
Smad Signal Transduction; 2006, p415-442, 28p |
| Abstrakt: |
TGF-β signaling in cancer can be modulated by a variety of different pharmacological agents, including small molecule inhibitors of the TGF-β type I receptor kinase. Such inhibitors are currently being developed by a number of pharmaceutical companies and may soon be clinically investigated. While such inhibitors progress through early clinical development, selecting patients, who most likely will benefit from this novel compound class, will be critical for determining the efficacy of the TβRI kinase inhibitors. In the present article, we review clinical studies examining the association of TGF-β/Smad signaling and clinical outcome. This review may help in the identification of the appropriate patient population to investigate the activity of future TGF-β/Smad inhibitors [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
